Close

Cellectis Amends $20 Million Convertible Note Under Collaboration Agreement with its Partner Cytovia Therapeutics Jan 20, 2023 04:30PM
Mayflower Bioventures Launches its First Spin-Out, Primera Therapeutics, in Strategic Collaboration with Cellectis to Develop a Gene Editing Platform to Treat Mitochondrial Diseases Dec 29, 2022 04:30PM
Calyxt Joins Bioindustrial Manufacturing and Design Ecosystem (BioMADE), a Department of Defense Initiative, to Advance Sustainable Plant-Based Biomanufacturing Nov 1, 2022 07:00AM
Omega Therapeutics Announces Appointment of Rainer Boehm to its Board of Directors Sep 1, 2022 07:00AM
Cytovia Therapeutics and Cellectis Partner to Develop TALEN® Gene-Edited iPSC-Derived Natural Killer Cells Feb 16, 2021 01:00AM


Mar 4, 2020 04:05PM Cellectis and Servier Execute the Amendment Confirming the Expansion of Their Collaboration on UCART19 Products
Apr 3, 2018 08:10AM Cellectis and Allogene Therapeutics Intend to Continue Strategic Cancer Immunotherapy Collaboration to Accelerate Development and Commercialization of Allogeneic Off-the-Shelf CAR T Therapies
Mar 8, 2018 04:30PM Cellectis: Servier and Pfizer Announce Results of UCART19 First-in-Human Trials to Be Presented at the 44th EBMT (European Society for Blood and Marrow Transplantation) Annual Meeting
Dec 12, 2017 06:38PM Preliminary Data from Servier and Pfizer’s UCART19 Product Candidate Shows High Complete Remission Rate Across Two Phase I Adult and Pediatric Acute Lymphoblastic Leukemia Trials
Nov 1, 2017 04:15PM Servier and Pfizer Announce Preliminary Results of the First-in-Human Trials of UCART19 Will Be Presented at the 59th American Society of Hematology (ASH) Annual Meeting
Mar 9, 2017 06:29AM Servier, Pfizer (PFE) Announce FDA Clearance of IND Application for UCART19 for B-ALL (CLLS)
Mar 9, 2017 02:00AM Servier and Pfizer Announce FDA Clearance of IND Application for UCART19 in Adult Relapsed/Refractory Acute Lymphoblastic Leukemia
Oct 14, 2015 09:05AM Market’s Only Cancer Immunotherapy ETF Launches
Apr 8, 2015 07:44AM Citi Appointed Depositary Bank for Cellectis’ ADR Programme